• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis.

作者信息

Shin Robert K, Rammohan Kottil W, Williams Mitzi J

机构信息

MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC, 20007, USA.

University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

Neurol Ther. 2021 Dec;10(2):415-425. doi: 10.1007/s40120-021-00266-z. Epub 2021 Aug 4.

DOI:10.1007/s40120-021-00266-z
PMID:34347280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8336531/
Abstract
摘要

相似文献

1
Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis.针对多发性硬化症患者的新冠疫苗接种专家观点
Neurol Ther. 2021 Dec;10(2):415-425. doi: 10.1007/s40120-021-00266-z. Epub 2021 Aug 4.
2
Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19.关于新冠疫情期间B细胞靶向疗法及其他多发性硬化症相关问题的播客
Neurol Ther. 2022 Jun;11(2):515-524. doi: 10.1007/s40120-021-00321-9. Epub 2022 Jan 23.
3
Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives.新冠疫情时代多发性硬化症免疫疗法的潜在风险与益处：临床与免疫学视角
Neurotherapeutics. 2021 Jan;18(1):244-251. doi: 10.1007/s13311-021-01008-7. Epub 2021 Feb 2.
4
[Vaccination against SARS-CoV-2 in patients with multiple sclerosis].[多发性硬化症患者的新型冠状病毒2型疫苗接种]
Rev Neurol. 2021 Apr 1;72(7):250-260. doi: 10.33588/rn.7207.2021097.
5
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.多发性硬化症患者与疾病修正疗法：对针对2019冠状病毒病和严重急性呼吸综合征冠状病毒2疫苗接种的免疫反应的影响
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
6
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.在接受疾病修正治疗的多发性硬化症患者中，SARS-CoV-2 感染的临床病程和结局-波兰经验。
Neurol Neurochir Pol. 2021;55(2):212-222. doi: 10.5603/PJNNS.a2021.0031. Epub 2021 Apr 15.
7
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.新型冠状病毒抗体阳性多发性硬化症患者中疾病修正治疗的安全性。
Mult Scler Relat Disord. 2021 Apr;49:102754. doi: 10.1016/j.msard.2021.102754. Epub 2021 Jan 13.
8
Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.在接受奥瑞珠单抗治疗的多发性硬化症患者中，辉瑞 - 生物科技公司疫苗接种后的抗严重急性呼吸综合征冠状病毒2抗体反应：一例报告
J Int Med Res. 2021 Sep;49(9):3000605211044378. doi: 10.1177/03000605211044378.
9
Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?当前多发性硬化症患者疫苗接种的免疫和临床观点：它们终究安全吗？
Int J Mol Sci. 2021 Apr 8;22(8):3859. doi: 10.3390/ijms22083859.
10
Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases.多发性硬化症合并 COVID-19 患者及疾病修正治疗的经验：873 例已发表病例的综述
J Clin Med. 2020 Dec 16;9(12):4067. doi: 10.3390/jcm9124067.

引用本文的文献

1
Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations.三个大型多发性硬化症群体中疾病修饰疗法的起始模式
Ther Adv Neurol Disord. 2024 Mar 15;17:17562864241233044. doi: 10.1177/17562864241233044. eCollection 2024.
2
Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids.骨骼肌与2019冠状病毒病：生物活性鞘脂的潜在作用
Biomedicines. 2022 May 4;10(5):1068. doi: 10.3390/biomedicines10051068.
3
Ocrelizumab: A Review in Multiple Sclerosis.奥瑞珠单抗：多发性硬化症的治疗药物。
Drugs. 2022 Feb;82(3):323-334. doi: 10.1007/s40265-022-01672-9. Epub 2022 Feb 22.
4
Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19.关于新冠疫情期间B细胞靶向疗法及其他多发性硬化症相关问题的播客
Neurol Ther. 2022 Jun;11(2):515-524. doi: 10.1007/s40120-021-00321-9. Epub 2022 Jan 23.

本文引用的文献

1
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.接受高效疾病修正治疗的多发性硬化症患者对新冠病毒mRNA疫苗的体液免疫反应
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. doi: 10.1177/17562864211012835. eCollection 2021.
2
Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine.新型冠状病毒肺炎的神经系统并发症：辉瑞新型冠状病毒肺炎疫苗接种后格林-巴利综合征
Cureus. 2021 Feb 18;13(2):e13426. doi: 10.7759/cureus.13426.
3
Burton's Agammaglobulinemia and COVID-19.伯顿无丙种球蛋白血症与新型冠状病毒肺炎
Cureus. 2020 Nov 25;12(11):e11701. doi: 10.7759/cureus.11701.